

Sruthi Adimadhyam

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7840168/publications.pdf>

Version: 2024-02-01

15
papers

215
citations

1307594

7
h-index

1199594

12
g-index

15
all docs

15
docs citations

15
times ranked

441
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk of amputations associated with SGLT2 inhibitors compared to DPP4 inhibitors: A propensity-matched cohort study. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2792-2799.	4.4	52
2	Tumor necrosis factor- α inhibitors and risk of non-Hodgkin lymphoma in a cohort of adults with rheumatologic conditions. <i>International Journal of Cancer</i> , 2018, 143, 1062-1071.	5.1	42
3	Increased risk of mycotic infections associated with sodium-glucose co-transporter 2 inhibitors: a prescription sequence symmetry analysis. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 160-168.	2.4	22
4	Sodium-glucose co-transporter 2 inhibitors and the risk of fractures: A propensity score-matched cohort study. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 1629-1639.	1.9	21
5	A trial of indication based prescribing of antihypertensive medications during computerized order entry to improve problem list documentation. <i>International Journal of Medical Informatics</i> , 2013, 82, 996-1003.	3.3	20
6	Risk of Nonmelanoma Skin Cancer in Association With Use of Hydrochlorothiazide-Containing Products in the United States. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkrab009.	2.9	17
7	Risk of Arrhythmias Associated with Ipratropium Bromide in Children, Adolescents, and Young Adults with Asthma: A Nested Case-Control Study. <i>Pharmacotherapy</i> , 2014, 34, 315-323.	2.6	12
8	Bevacizumab Use and the Risk of Arterial and Venous Thromboembolism in Patients with High-Grade Gliomas: A Nested Case-Control Study. <i>Pharmacotherapy</i> , 2019, 39, 921-928.	2.6	8
9	Arterial and Venous Thromboembolic Safety of Bevacizumab in Patients with High Grade Gliomas. <i>Blood</i> , 2018, 132, 2280-2280.	1.4	8
10	Targets of biologic disease-modifying antirheumatic drugs and risk of multiple myeloma. <i>International Journal of Cancer</i> , 2020, 147, 1300-1305.	5.1	6
11	Treatment of older patients with diffuse large B-cell lymphoma and mild cognitive impairment or dementia. <i>Journal of Geriatric Oncology</i> , 2019, 10, 510-513.	1.0	4
12	Mediation analyses of socioeconomic factors determining racial differences in the treatment of diffuse large B-cell lymphoma in a cohort of older adults. <i>Medicine (United States)</i> , 2019, 98, e17960.	1.0	3
13	Race and Socioeconomic Factors Influencing Treatment Disparities and Comparative Effectiveness in Very Elderly Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 841-841.	1.4	0
14	Racial Differences in Long-Term Risk of Venous Thromboembolism Among Older Patients Following Diagnosis and Treatment of Multiple Myeloma. <i>Blood</i> , 2016, 128, 2071-2071.	1.4	0
15	Biologic Disease-Modifying Antirheumatic Drugs and Risk of Multiple Myeloma. <i>Blood</i> , 2018, 132, 1888-1888.	1.4	0